feeling sick; swollen lymph nodes near the ear; weakness; tiredness; pain; shingles on the face (forehead, eye, right); this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory authority-web. the reporter is the patient. regulatory number: at-basgages-2021-065561 . a 67 year-old male patient received bnt162b2 (comirnaty), administration date 25nov2021 (batch/lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. vaccination history included: covid-19 vaccine (1st dose, manufacturer unknown), for covid-19 immunisation; covid-19 vaccine (2nd dose, manufacturer unknown), for covid-19 immunisation. the following information was reported: malaise (medically significant) with onset 01dec2021, outcome "recovered", described as "feeling sick"; lymphadenopathy (medically significant) with onset 01dec2021, outcome "recovered", described as "swollen lymph nodes near the ear"; asthenia (medically significant) with onset 01dec2021, outcome "recovered", described as "weakness"; fatigue (medically significant) with onset 01dec2021, outcome "recovered", described as "tiredness"; pain (medically significant) with onset 01dec2021, outcome "recovered", described as "pain"; herpes zoster (medically significant) with onset 01dec2021, outcome "recovered", described as "shingles on the face (forehead, eye, right)". therapeutic measures were taken as a result of malaise, lymphadenopathy, asthenia, fatigue, pain, herpes zoster. clinical course: shingles on the face (forehead, eye, right) tiredness, weakness, feeling sick, pain, swollen lymph nodes near the ear. treatment given for shingles included viropel 1000 film-coated tablets, ointment. outcome improved, crust still present. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected